Induction of Noxa Sensitizes Human Colorectal Cancer Cells Expressing Mcl-1 to the Small-Molecule Bcl-2/Bcl-xL Inhibitor, ABT-737

Kenji Okumura, Shengbing Huang, and Frank A. Sinicrope

**Abstract**

**Purpose:** The intrinsic drug resistance of colorectal cancers is related in part to overexpression of prosurvival Bcl-2 family proteins. We determined the effects of ABT-737, a small-molecule inhibitor of Bcl-2/Bcl-xL but not Mcl-1, on apoptosis induction alone and in combination with CPT-11 and explored mechanisms underlying their cooperativity.

**Experimental Design:** Human colorectal carcinoma cell lines (HCT116 wild-type and Bax−/−, HT-29, and RKO) were incubated with ABT-737 alone and combined with CPT-11 or bortezomib, and cell viability, caspase cleavage, and Annexin V labeling were measured. In drug-treated cell lines, protein-protein interactions were analyzed by immunoprecipitation. Lentiviral short hairpin RNA was used to knockdown Noxa expression.

**Results:** ABT-737 induced apoptosis in a dose-dependent manner and its coadministration with the topoisomerase I inhibitor, CPT-11, resulted in a synergistic cytotoxic effect. Apoptosis induction by the drug combination was associated with enhanced caspase-8, caspase-9, and caspase-3 activation and poly(ADP-ribose) polymerase cleavage that were completely abrogated in Bax knockout cells. ABT-737 unsequestered the BH3-only protein Bim from its complex with Bcl-xL or Bcl-2 and disrupted the interaction of Bcl-xL with Bak. CPT-11 treatment up-regulated Noxa expression, as did bortezomib, and enhanced Noxa/Mcl-1 complexes. CPT-11 also disrupted the Mcl-1/Bak interaction. Knockdown of Noxa using short hairpin RNA lentiviral constructs was shown to significantly attenuate the cytotoxic effect of CPT-11 or bortezomib combined with ABT-737 and inhibited caspase-3 cleavage.

**Conclusions:** Induction of Noxa by CPT-11 or bortezomib can sensitize colorectal cancer cells expressing Mcl-1 to ABT-737. Up-regulation of Noxa may therefore represent an important strategy to enhance the therapeutic efficacy of ABT-737 against colorectal cancer and other solid tumors.

Colorectal cancer is the third most common cancer and second leading cause of cancer-related mortality in the United States (1). This malignancy displays intrinsic apoptosis resistance related to the overexpression of prosurvival Bcl-2 proteins (2). Accordingly, new drugs are needed to circumvent Bcl-2-mediated resistance and to increase therapeutic efficacy. Proapoptotic BH3-only proteins are sensors of cellular stresses, including chemotherapeutic drugs, which bind to the hydrophobic cleft in prosurvival Bcl-2 family proteins to neutralize them, thereby shifting the balance in favor of proapoptotic molecules. Disabling prosurvival Bcl-2 proteins removes their restraint of downstream Bax and Bak. At least eight BH3-only members have been identified and these include Bad, Bid, Bik, Bim, Bmf, Hrk, Noxa, and Puma (3). The BH3-only proteins can be further divided into two subclasses: “activators” (e.g., Bim and tBid), which directly activate Bax/Bak to induce mitochondria outer membrane permeabilization, and “sensitizers” (e.g., Bad, Bik, Bmf, Hrk, Noxa, and Puma), which do not activate Bax/Bak directly but instead neutralize prosurvival proteins (4). Studies indicate that BH3-only proteins bind promiscuously or selectively to prosurvival Bcl-2 proteins (5–7). Bim and Puma have been shown to target all prosurvival proteins and, accordingly, are more potent inducers of apoptosis in vitro than are Bad and Noxa which target only a subset (6).

Recently, BH3 mimetics have been developed as a new and novel class of anticancer drugs. ABT-737 is a BH3 mimetic and potent small-molecule antagonist that binds with high affinity to Bcl-2, Bcl-xL, and Bcl-w but not Mcl-1 (8). ABT-737 has been shown to lower the apoptotic threshold for certain chemotherapeutic agents and also showed impressive preclinical activity against lymphoma in a murine model (8, 9). ABT-737 has

**Authors’ Affiliations:** Miles and Shirley Fiterman Center for Digestive Diseases and Division of Oncology, Mayo Clinic, Rochester, Minnesota

**Grant support:** National Cancer Institute R01 grant CA104683-02 (F.A. Sinicrope), Japan-North America Medical Exchange Foundation (K. Okumura), and Mayo Clinic Cancer Center National Cancer Institute core grant CA15083.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

**Note:** Supplementary data for this article are available at Clinical Cancer Research Online (http://clincancerres.aacrjournals.org/).

K. Okumura and S. Huang contributed equally to this work.

**Requests for reprints:** Frank A. Sinicrope, Miles and Shirley Fiterman Center for Digestive Diseases and Division of Oncology, Mayo Clinic, 200 1st Street Southwest, Rochester, MN 55905. E-mail: sinicrope.frank@mayo.edu.

(© 2008 American Association for Cancer Research. doi:10.1158/1078-0432.CCR-08-1665)

**Cancer Therapy: Preclinical**
Translational Relevance

Colorectal cancers display intrinsic drug resistance due to overexpression of prosurvival Bcl-2 family proteins. Recently, small-molecule antagonists of Bcl-2 proteins, also known as BH3 mimetics, have been developed and represent a promising therapeutic strategy. These novel compounds bind to the BH3 domain of prosurvival Bcl-2 proteins to neutralize them and thus enable Bak and Bad activation. BH3-only proteins, including Noxa, are induced by cellular stress including chemotherapy, and gene knockout or suppression of BH3 protein expression confers apoptosis resistance. ABT-737 is a BH3 mimic that selectively inhibits Bcl-2 and Bcl-xL but not Mcl-1. Therefore, strategies to disable Mcl-1 may increase the efficacy of ABT-737. Noxa is a high-affinity binding partner of Mcl-1, and in human colon carcinoma cells, we show that CPT-11 or bortezomib can induce Noxa expression and thereby sequester Mcl-1 to enhance apoptosis induction. Therefore, induction of Noxa in cancer cells expressing Mcl-1 represents a promising strategy to increase the therapeutic efficacy of ABT-737.

Materials and Methods

**Cell culture, drugs, and reagents.** Human colorectal cancer cell lines HCT116, HT-29, RKO, and HCT116 Bax−/− knockout cells (gift of Dr. B. Vogelstein, Johns Hopkins University) were used. Cell lines were cultured in RPMI 1640 (Invitrogen) supplemented with 10% fetal bovine serum and with 1% penicillin/streptomycin, 10 mmol/L HEPES, and 1% sodium pyruvate. ABT-737 (Abbott), CPT-11 (Sigma), SN-38 (United States Biological), or bortezomib (PS-341; Millennium) were dissolved in DMSO to produce 20 or 10 mmol/L stock solutions that were aliquoted and stored at −20°C.

**Cell viability assay.** Cell viability was determined in the presence or absence of drug treatment using the MTS reduction assay per the manufacturer’s protocol (Promega), as previously described (17). To exclude interference by CPT-11 or SN-38 in the MTS assay, we added each drug individually in the absence of cells and showed no change in absorbance.

**Annexin V staining.** After drug treatment, adherent cells were detached from culture dishes by treating with Accutase (Innovative Cell Technologies) for 5 to 15 min and combined with floating cells. Total cells were then washed with cold PBS twice and resuspended in 1× Annexin V binding buffer (BD Bioscience) at a concentration of 1 × 10^6 to 1 × 10^7 cells/mL. A single-cell suspension (100 µL) was stained with 10 µL Annexin V-FTC (BD Bioscience) for 15 min at room temperature in the dark. Propidium iodide (10 µL; Sigma) and 1× Annexin V binding buffer (380 µL) were then added to each tube. Two-color (FL1 and FL2) flow cytometry analysis was then done on a FACScan (Becton Dickinson). A minimum of 10,000 cells per sample were analyzed.

**Immunoprecipitation and Western blotting.** Mock-treated or drug-treated cells were harvested by scraping and then washed in cold PBS. After cell lysis, the cell pellet was lysed in CHAPS buffer [5 mmol/L MgCl₂, 137 mmol/L KCl, 1 mmol/L EDTA, 1 mmol/L EGTA, 1% CHAPS, 10 mmol/L HEPES (pH 7.5)] for 30 min on ice with protease inhibitors (5 mmol/L phenylmethylsulfonyl fluoride, 10 µg/mL aprotinin, 10 µg/mL leupeptin, and 10 µg/mL pepstatin). The cell lysate was subjected to IP as previously described (17). The antibodies used were as follows: Bim (Santa Cruz Biotechnology), Bak (Upstate Biotechnology), and Mcl-1 (BD Biosciences). Western blotting was performed as previously described (17). The antibodies used are as follows: Bcl-2 (BD Biosciences); Bcl-xL (Cell Signaling); Mcl-1 (BD Biosciences); Bax (Cell Signaling); Bak (Upstate Biotechnology); β-tubulin (Sigma); caspase-8 (BD Biosciences); Bid, caspase-9, and cleaved caspase-3 (all from Cell Signaling); poly(ADP-ribose) polymerase (Biomol); Bim (Santa Cruz Biotechnology); Puma (Cell Signaling); Noxa (Calbiochem); and p53 (Cell Signaling).

**Knockdown of Noxa using lentiviral short hairpin RNA.** Target sequences for Noxa and a control sequence were selected and short hairpin RNA (shRNA) template oligonucleotides (synthesized by the Mayo Clinic Molecular Biology Core Facility) were ligated into the lentiviral shRNA cloning and expression vector pSH1-H1 (System Bioscience) using a quick ligation kit (New England Biolabs). Insertion sequence at the intended site was confirmed by sequencing. The control shRNA sequence was AATAGCGACTAAACACATCAA (18). The targeting sequences for Noxa were GTAATTATGACACAGATTCTCCTT (Noxa) and GAAGTGTGATCCTGACTG (Noxa 3; refs. 19, 20). For lentivirus production, 2 µg endotoxin-free lentiviral shRNA expression construct DNA was mixed with 20 µg lentivector packaging plasmid DNA mix (System Bioscience) and diluted in 400 µL serum reduction medium (Opti-MEM; Invitrogen) containing 20 µL Plus reagent (Invitrogen). After incubation at room temperature for 15 min, 30 µL Lipofectamine reagent mixed with 400 µL Opti-MEM was added dropwise into the above DNA/Plus complex and incubated for another 15 min. The lentivirus producer cell line 293T was transfected with the DNA/ Lipofectamine/Plus complex overnight in Opti-MEM in the 5% CO₂ incubator at 37°C. The next day, the medium was replaced with fresh DMEM containing 2% heat-activated fetal bovine serum and incubation at 37°C was continued. At 48 h post-transfection, the supernatants were collected, clarified, and filtered through Millex-HV 0.45-µm polyvinylidene difluoride filters (Millipore). The supernatants were concentrated by adding 10% (final concentration) of PEG-8000 (Sigma), incubating

www.aacnjournals.org
Downloaded from clincancerres.aacnjournals.org on January 13, 2018. © 2008 American Association for Cancer Research.
at 4°C overnight for no less than 12 h, and centrifuged at 1,500 × g for 10 min at 4°C. For transduction of the lentiviral shRNA expression construct (packaged in pseudotyped viral particles) into target cells, the growth medium of target cells was replaced with Opti-MEM containing 8 µg/mL polybrene (Sigma) and appropriate amounts of lentivirus. The cells were incubated overnight at 37°C. The medium was replaced with normal growth medium the following day. The efficiency of knockdown was tested 72 h post-transduction. Alternatively, 2 to 4 µg/mL puromycin (Sigma) was added at 48 h post-transduction and the puromycin-resistant pool of cells was used for subsequent experiments. 

Calculation of combination index. The effect of combination between ABT-737 and CPT-11 at a fixed ratio (1:1) was analyzed using CalcuSyn software (Biosoft) as reported previously (21).

Statistical analysis. The values shown represent the mean ± SD for triplicate experiments. The statistical significance of the differences between experimental variables was determined using the Student's t test. P < 0.05 was considered statistically significant.

Results

ABT-737 and CPT-11 cooperatively enhance cytotoxicity due to apoptosis. Treatment of HCT116 and HT-29 cell lines with ABT-737 (5-10 µmol/L) alone produced a modest reduction in cell viability. Furthermore, coadministration of ABT-737 (5-10 µmol/L) and CPT-11 (2.5-10 µmol/L) was shown to reduce cell viability to...
a greater extent than did either drug alone (Fig. 1A and B). To determine whether the cytotoxic effect of the drug combination was synergistic or additive, we performed an analysis using the median effect method. HCT116 and HT-29 cell lines were treated with ABT-737 or CPT-11 for 48 h and their IC\textsubscript{50} values were calculated (Fig. 1C and D). The cell lines were treated with different concentrations of ABT-737 and CPT-11 at a fixed ratio (1:1) and cell viability was determined. The combination index (CI) was then calculated per the method of Chou and Talalay (22). As shown in an isobologram, the CI values in HCT116 cells were <1, indicating a synergistic interaction (Fig. 1C). In HT-29 cells, calculation of the CI revealed that the combination of ABT-737 and CPT-11 was additive (Fig. 1D).

We analyzed and quantified the apoptotic effect of ABT-737 or CPT-11 alone and in combination by Annexin V staining. ABT-737 plus CPT-11 induced apoptosis to a greater extent than did either drug alone in both cell lines (Fig. 2A-C). ABT-737 induced apoptosis to a greater extent in HCT116 versus HT-29 cells, which may be explained by lower levels of endogenous Mcl-1 and higher levels of Bcl-2 in HCT116 cells (Fig. 2D). Furthermore, the drug combination produced a 1.7-fold increase in cell death compared with ABT-737 (5 \textmu mol/L) alone in HT-29 cells versus a 3.5-fold increase in HCT116 cells.

**ABT-737 and CPT-11 cooperatively enhance apoptotic signaling.** Exposure of HCT116 and HT-29 cell lines to the combination of ABT-737 plus CPT-11 resulted in enhanced activation of caspase-8, caspase-9, and caspase-3 and cleavage of Bid and poly(ADP-ribose) polymerase (PARP) compared with treatment with either drug alone (Fig. 3A). To determine whether drug-induced caspase-8 activation is due to a feedback amplification loop mediated by caspase-3 (23), we used a caspase-3 inhibitor (z-DEVD-FMK). z-DEVD-FMK was shown to attenuate caspase-8 cleavage by ABT-737 and its combination with CPT-11 in HCT116 cells (Fig. 3B), consistent with a
feedback amplification loop mediated by caspase-3. To confirm that cell death occurred by an apoptotic mechanism, Bax knockout HCT116 cells were used. Treatment of these cells with ABT-737, CPT-11, or their combination failed to activate caspases or to cleave PARP (Fig. 3C), and their cytotoxic effects were completely abrogated (Fig. 3D).

Given that SN-38 is the active metabolite of CPT-11, we evaluated the effects of the combination of SN-38 and ABT-737 on caspase activation and cytotoxicity. SN-38 was used at nanomolar dosages because it has been shown to be ~1,000-fold more potent than CPT-11 (15, 24, 25). The combination with SN-38 and ABT-737 enhanced caspase cleavage (Fig. 4A) and cooperatively reduced cell viability (Fig. 4B) to a greater extent than did either drug alone in HCT116 cells. We determined the IC50 value for SN-38 (53.9 nmol/L) and evaluated the combination of SN-38 and ABT-737 at fixed ratios. Calculation of the CI of SN-38 and ABT-737 yielded CI < 1, indicating a synergistic interaction, as shown in an isobologram (Fig. 4C). We also measured apoptosis induction by SN-38, ABT-737, or their combination by Annexin V staining. The drug combination induced apoptosis to a greater extent than did either drug alone (Fig. 4D).

**Fig. 3.** ABT-737 and CPT-11 enhance Bax-dependent apoptotic signaling. A, human colon carcinoma cell lines HCT116 or HT-29 were incubated with vehicle (DMSO), ABT-737 (10 μmol/L), CPT-11 (10 μmol/L), or their combination for 24 h. The effects of drug treatment on cleavage of caspases, Bid, and poly(ADP-ribose) polymerase (PARP) were determined in whole-cell lysates subjected to immunoblotting. β-Tubulin served as a control for protein loading. B, HCT116 cells were incubated with vehicle (DMSO) or ABT-737 (10 μmol/L) alone or in combination with CPT-11 (10 μmol/L) for 24 h and caspase-8 and caspase-3 cleavage were analyzed in the presence or absence of a caspase-3 inhibitor (z-DEVD-FMK, 20 μmol/L). Experiments were done in whole-cell lysates subjected to immunoblotting. C, HCT116 Bax−/− cells were incubated with vehicle (DMSO), ABT-737 (10 μmol/L), CPT-11 (10 μmol/L), or their combination for 24 h. Caspase-8, caspase-9, and caspase-3 cleavage and Bid and PARP cleavage were determined. D, effect of ABT-737 and/or CPT-11 at the indicated doses on cell viability (MTS assay; 48 h) was also determined in HCT116 Bax−/− cells. Experiments were conducted in triplicate. Mean ± SD.
can potentiate CPT-11-induced apoptosis. As a BH3 mimic, ABT-737 binds to and neutralizes Bcl-2/Bcl-xL and can thereby disrupt important protein-protein interactions. Bim can bind to all prosurvival Bcl-2 proteins and is therefore a potent proapoptotic molecule (3). We determined the effect of ABT-737 treatment on the interaction between Bim and Bcl-2 proteins by immunoprecipitation of Bim and then probing for Bcl-xL, Bcl-2, and Mcl-1. ABT-737 treatment was shown to

---

**Fig. 4.**  
A. HCT116 cells were incubated with ABT-737 (10 μmol/L), SN-38 (10 nmol/L), or their combination for 24 h. DMSO was used as a vehicle control. The effects of drug treatment on caspase cleavage and Bid were analyzed by immunoblotting.  
B. Cytotoxic effects of ABT-737 and/or SN-38 treatment for 48 h at indicated doses were determined using the MTS assay. Experiments were conducted in triplicate. Mean ± SD. Inset, treatment of HCT116 cells with SN-38 (10 nmol/L) was shown to induce Noxa expression.  
C. IC50 values for SN-38 were calculated. Cells were treated with ABT-737 and SN-38 at a fixed ratio (500:1) and the CI was calculated (see Materials and Methods). An isobologram showing CI < 1 indicates synergy.  
D. Apoptosis was determined using Annexin V and propidium iodide staining in HCT116 cells treated with vehicle (DMSO), SN-38, ABT-737, or their combination for 24 h at the indicated doses by FACS analysis.
Whole-cell lysates (vehicle (DMSO) for 24 h and immunoprecipitation was done for Bim proteins. Whole-cell lysates were then probed for Bak or Bcl-xL proteins.

ABT-737 also displaced Bim from its complex with Bcl-xL in HCT116 cells compared with control-treated cells (Fig. 5A). Noxa is a BH3-only protein whose expression can be induced by p53-dependent or p53-independent apoptotic stimuli (27). In HCT116 (wild-type p53) but not HT-29 (mutated p53) cells, CPT-11 treatment markedly induced expression of Noxa and also up-regulated Bak compared with vehicle-only treated cells (Fig. 6A). We also found that SN-38 significantly up-regulated Noxa expression in HCT116 cells (Fig. 4B). Given the induction of Noxa by CPT-11 in HCT116 cells, we determined the effect of drug treatment on the interaction between Noxa and its high-affinity partner Mcl-1 that result in Noxa/Mcl-1 complexes (3, 19). To address this issue, we immunoprecipitated Mcl-1 and probed for Noxa in HCT116 cells treated with CPT-11 or vehicle. CPT-11 treatment was shown to enhance the interaction of Mcl-1 and Noxa (Fig. 6B). It has been proposed that up-regulation of Noxa can activate Bak by displacing it from Mcl-1 (26). Consistent with this model, treatment with CPT-11 was shown to release Bak from its interaction with Mcl-1 (Fig. 6B). Although a prior study suggested that Mcl-1 binding of endogenously induced Noxa can interfere with the ability of Mcl-1 to sequester Bim (28), CPT-11 treatment failed to show an appreciable effect on Mcl-1 and Bim complexes (Fig. 6B). Taken together, induction of Noxa by CPT-11 can sequester Mcl-1 and also release Bak from Mcl-1, which may contribute to the enhanced apoptotic effect of the CPT-11 and ABT-737 combination.

Knockdown of Noxa attenuates the cytotoxicity of CPT-11 plus ABT-737. To further show the importance of Noxa up-regulation as a potential mechanism for the synergistic cytotoxic effect of CPT-11 and ABT-737, we generated Noxa knockdown HCT116 cells using lentiviral-delivered shRNA. Knockdown of Noxa was found to significantly reduce sensitivity to CPT-11 plus ABT-737 as shown using two shRNA constructs (Fig. 6C; Supplementary Fig. S1). Furthermore, Noxa knockdown blocked the activation of caspase-3 induced by the drug combination (Fig. 6C). Because CPT-11 did not induce Noxa in HT-29 cells, we generated Noxa knockdown HT-29 cells. Knockdown of Noxa had no effect on the sensitivity of HT-29 cells to the combination of ABT-737 and CPT-11, although a slight protection was seen at an ABT-737 dose of 10 μmol/L (Fig. 6D). At a dose of 10 μmol/L, ABT-737 was shown to weakly induce Noxa (Fig. 6D). Together, these data show that Noxa is a key regulator of apoptotic susceptibility to this drug combination.

To show that induction of Noxa represents an important mechanism to increase apoptotic susceptibility, we used the proteasome inhibitor bortezomib that has been shown to induce Noxa in human myeloma cells (19), mantle-cell lymphoma cells (29), and non-small cell lung cancer cells (30). Treatment of HCT116 and HT-29 cell lines with bortezomib (20-60 nmol/L) was shown to markedly induce Noxa in both cell lines (Fig. 7A). Coadministration of ABT-737 and bortezomib was shown to enhance caspase cleavage (Fig. 7B) and to enhance cytotoxicity in both cell lines to a greater extent compared with either drug alone (Fig. 7C). Using Noxa knockdown HCT116 and HT-29 cells, we observed that Noxa shRNA protected cells from caspase-3 cleavage and cytotoxicity induced by bortezomib plus ABT-737 (Fig. 7D). We also found that CPT-11 can induce Noxa in another colon cancer cell line, RKO, which expresses high levels of Mcl-1. In these cells, ABT-737 was again shown to enhance CPT-11-mediated cytotoxicity and caspase cleavage (Supplementary Fig. S2). These data suggest that our findings can be generalized to other colon cancer cell lines.

Discussion

ABT-737 is a potent small-molecule antagonist of prosurvival Bcl-2 proteins (8). Although sparse data exist as to the activity of ABT-737 in solid tumor cell lines, this drug has been shown to lower the apoptotic threshold for certain chemotherapeutic agents (8, 12). Colorectal cancers display intrinsic apoptosis resistance related, in part, to overexpression of prosurvival Bcl-2 proteins (2). Therefore, we determined whether the combination of ABT-737 and CPT-11 exerts an enhanced apoptotic effect
CPT-11 up-regulates Noxa to sequester Mcl-1 and to disrupt Mcl-1/Bak complexes. Knockdown of Noxa attenuates the cytotoxicity of CPT-11 plus ABT-737. The effect of CPT-11 treatment on the expression of BH3-only and proapoptotic proteins was determined. A, HCT116 and HT-29 cells were incubated with CPT-11 (10 μmol/L) for 48 h and whole-cell lysates were subjected to immunoblot analysis for the expression of indicated proteins. B, HCT116 cells were treated with vehicle (DMSO) or CPT-11 (10 μmol/L) for 24 h and immunoprecipitation was done for Mcl-1 proteins. Whole-cell lysates from beads and eluted proteins from beads were separated by SDS-PAGE and then probed for Mcl-1, Bim, Noxa, or Bak proteins. C and D, knockdown of Noxa was achieved using lentiviral-delivered shRNA in HCT116 (C, left) or HT-29 (D, left) cells and the level of Noxa expression was determined in untreated (vehicle) and drug-treated cells by immunoblotting. HCT116 cells (C, left) were treated with vehicle (DMSO) or the combination of ABT-737 and CPT-11 at the indicated doses for 24 h and caspase-3 cleavage was analyzed in whole-cell lysates subjected to immunoblotting. β-Tubulin served as a control for protein loading. We then determined the effect of Noxa knockdown versus control shRNA on cell viability in drug-treated HCT116 (C, right) and HT-29 (D, right) cell lines. Cell viability was determined using two Noxa shRNA constructs in HCT116 cells, and similar results for the Noxa and Noxa 3 (Supplementary Fig. S1) constructs were found. Cells were incubated with ABT-737 and/or CPT-11 for 48 h at the indicated doses and cell viability was determined using the MTS assay. Experiments were conducted in triplicate. Mean ± SD. *P < 0.005; **P < 0.0005.
Fig. 7. Bortezomib up-regulates Noxa to cooperatively enhance the effects of ABT-737 on cytotoxicity and apoptosis. A, HCT116 and HT-29 cells were treated with bortezomib (20–60 nmol/L) and Noxa expression was analyzed by immunoblotting. Cells were treated with bortezomib (20 nmol/L) or vehicle (DMSO) for 24 h and Bim, Puma, and Noxa expression was determined in whole-cell lysates by immunoblot analysis. B, HCT116 and HT-29 cells were incubated with vehicle (DMSO), ABT-737 (10 μmol/L), and/or bortezomib (20 nmol/L) for 24 h and their effects on caspase cleavage were analyzed in whole-cell lysates subjected to immunoblotting. α-Tubulin served as a control for protein loading. C, cytotoxic effects of ABT-737 and/or bortezomib treatment for 48 h at indicated doses were determined in HCT116 and HT-29 cells using the MTS assay. Experiments were conducted in triplicate. Mean ± SD. D, knockdown of Noxa was achieved using lentiviral-delivered shRNA in HCT116 (left) and HT-29 (right) cells. Cells were incubated with ABT-737 (10 μmol/L) and bortezomib (20 nmol/L) or vehicle (DMSO) for 24 h. Noxa expression and caspase-3 cleavage were then analyzed by immunoblotting. α-Tubulin served as a control for protein loading. The effects of ABT-737 and/or bortezomib treatment (48 h) at indicated doses on cell viability were determined using the MTS assay in the presence of Noxa shRNA or control shRNA-transduced HCT116 (left) and HT-29 (right) cell lines. Experiments were conducted in triplicate. Mean ± SD. * P < 0.005; ** P < 0.0005.
in human colon cancer cells. We found that ABT-737 mono-
therapy induced a dose-dependent apoptosis in HCT116 and
HT-29 colon cancer cells. Moreover, we show that coadminis-
tration of ABT-737 with CPT-11 results in a synergistic (HCT116)
or additive (HT-29) cytotoxic effect that is caspase-dependent and
requires Bax as shown using Bax knockout HCT116 cells
where caspase cleavage and apoptosis induction were completely
abrogated. We also show that nanomolar doses of SN-38, the
active metabolite of CPT-11, in combination with ABT-737
exerts a synergistic cytotoxic effect that is due to apoptosis.
Highly concordant results with SN-38 and CPT-11 support the
biological relevance of our observations.

The ability of ABT-737 to enhance apoptosis induction was
due to its ability to disrupt the interaction of Bcl-xL with Bak
and to displace Bim from its sequestration by Bcl-xL or Bcl-2 in
both cell lines. Recent studies have shown the importance of
unsequestering Bak from Bcl-xL in determining the lethality of
ABT-737 (26). We also found that CPT-11 releases Bak from
Mcl-1; together, these data for ABT-737 and CPT-11 are
consistent with the indirect activation model (3). Recently,
we (17) reported that ABT-737 can release Bim from Bcl-2 or
Bcl-xL and that Bim shRNA can attenuate the cytotoxic effects
of ABT-737 and TRAIL in human pancreatic cancer cell lines.
Potentially, the ABT-737-induced dissociation of Bim from Bcl-
2 or Bcl-xL may contribute to Bak activation. In this regard, Bim
may act directly on Bax/Bak as shown by the observation that
Bim, but not a Puma BH3 peptide, was sufficient to induce
oligomerization and activation of Bax and Bak to permeabilize
the outer mitochondrial membrane (5). Further evidence for
the direct activation model is that activation of Bax or Bak by
Bim has been shown in thymocytes from Bim/Bax or Bim/Bak
double-knockout mice (31). Bim is a potent inducer of
apoptosis because Bim, Puma, and tBid can neutralize all
prosurvival Bcl-2 proteins, whereas Bad and Noxa show
selectivity (6).

The ability of ABT-737 to release Bim from Bcl-xL or Bcl-2 may
enable its complex formation with Mcl-1, as shown in both cell
lines, and this Bim:Mcl-1 complex may attenuate the apoptotic
effect of ABT-737. Unsequestered Bim has been shown to
stabilize Mcl-1 (32) and this may account for the increase in Mcl-
1 expression seen in ABT-737-treated cells. We found that CPT-
11 or SN-38 treatment up-regulated Noxa expression in HCT116
cells, consistent with the role of BH3-only proteins, which act
as molecular sensors of cellular stress or damage (6, 26, 33).
Furthermore, CPT-11 was shown to increase Noxa/Mcl-1
complexes and also to disrupt the interaction of Mcl-1 with
Bak. This finding is consistent with the observation that up-
regulated Noxa promotes Bak activation by displacing it from
Mcl-1 (26, 29). Noxa can bind specifically to Mcl-1 and A-1 but
not to Bcl-2 or Bcl-xL (6). Higher Noxa levels have been observed
in cell lines sensitive to ABT-737, and ectopic expression of Noxa
in a resistant cell line increased its sensitivity to ABT-737 (12).
The converse has been shown for Mcl-1 in that ABT-737 binds
to Mcl-1 with low affinity; thus, Mcl-1 reduces responsiveness to
ABT-737 (12, 13). To confirm the importance of Noxa in the
synergistic cytotoxicity of CPT-11 plus ABT-737, suppression of
Noxa by shRNA was shown to markedly attenuate the cytotoxic
effect of this drug combination and blocked caspase-3 cleavage
in HCT116 cells. In HT-29 cells where CPT-11 did not induce
Noxa, knockdown of Noxa failed to confer resistance to CPT-11
plus ABT-737. To confirm the role of Noxa in sensitizing cells to
apoptosis, we used bortezomib that is known to induce Noxa in
myeloma cells (19) and did so in our colon cancer cell lines. The
combination of bortezomib and ABT-737 enhanced apoptosis
induction in HCT116 and HT-29 cells compared with either drug
alone, and this effect was attenuated using Noxa shRNA
constructs.

In summary, we show that ABT-737 and CPT-11 induce a
cooperative cytotoxic effect against human colorectal carcino-
mas cell lines. ABT-737 antagonizes Bcl-2/Bcl-xL to release Bim
and Bak. Although ABT-737 does not target Mcl-1 (10, 11), our
data indicate that CPT-11-induced up-regulation of Noxa can
sequester Mcl-1 and thereby disrupt Mcl-1/Bak complexes to
enhance apoptotic susceptibility. Together, these findings
suggest that Noxa induction can sensitize tumors expressing
Mcl-1 to ABT-737 and thereby suggest a strategy to improve the
therapeutic efficacy of ABT-737 against human colorectal
cancers.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Acknowledgments
We thank Dr. Scott Kaufmann (Mayo Clinic) for assistance in the calculation of IC50 values and the CI.

References
2. Violette S, Poullain L, Dussaux E, et al. Resistance of colon cancer cells to long-term 5-fluorouracil expo-
sure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status. Int J Cancer
26:1324–37.
67:2908–11.
Bcl-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 2005;17:
525–35.
6. Chen L, Willis SN, Wei A, et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands
11. van Delft MF, Wei AH, Mason KD, et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and ef-
12. Tahir S, Yang X, Anderson MG, et al. Influence of Bcl-2 family members on the cellular response of small-
13. Chen S, Dai Y, Harada H, Dent P, Grant S. Mcl-1 down-regulation potentiates ABT-737 lethality by co-
of the topoisomerase I inhibitor 7-ethyl-10-[4-[1-piperidino]-1-piperidino]-carbonylloxycamptothecin
against human tumor xenografts: lack of cross-resistance in vivo in tumors with acquired resistance to the


Induction of Noxa Sensitizes Human Colorectal Cancer Cells Expressing Mcl-1 to the Small-Molecule Bcl-2/Bcl-xL Inhibitor, ABT-737

Kenji Okumura, Shengbing Huang and Frank A. Sinicrope


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/14/24/8132

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2009/01/16/14.24.8132.DC1

Cited articles
This article cites 33 articles, 18 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/14/24/8132.full#ref-list-1

Citing articles
This article has been cited by 14 HighWire-hosted articles. Access the articles at:
http://clincancerres.aacrjournals.org/content/14/24/8132.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link
http://clincancerres.aacrjournals.org/content/14/24/8132.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.